Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study.
Saved in:
| Title: | Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study. |
|---|---|
| Authors: | Ngan J; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.; Department of Medicine, University of Melbourne, Fitzroy, Victoria, Australia., Kong YW; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia., Goad J; Department of Medicine, University of Melbourne, Fitzroy, Victoria, Australia., Huang MLH; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Jenkins A; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.; Department of Medicine, University of Melbourne, Fitzroy, Victoria, Australia.; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Victoria, Australia., Vogrin S; Department of Medicine, University of Melbourne, Fitzroy, Victoria, Australia., Trawley S; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.; Cairnmillar Institute, Hawthorn, Victoria, Australia., Manzoney A; Department of Endocrinology and Centre for Research in Education in Diabetes and Obesity, Austin Health, Heidelberg, Victoria, Australia., Nakano M; Department of Endocrinology and Centre for Research in Education in Diabetes and Obesity, Austin Health, Heidelberg, Victoria, Australia., Ekinci E; Department of Medicine, University of Melbourne, Fitzroy, Victoria, Australia.; Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Victoria, Australia.; Department of Endocrinology and Centre for Research in Education in Diabetes and Obesity, Austin Health, Heidelberg, Victoria, Australia., Kriketos A; Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Parkville, Victoria, Australia., Fourlanos S; Department of Medicine, University of Melbourne, Fitzroy, Victoria, Australia.; Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Victoria, Australia.; Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.; Department of Medicine, The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia., Boisseau L; Department of Diabetes and Endocrinology, Canberra Health Services, Garran, Canberra, Australia., Nolan CJ; Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Victoria, Australia.; Department of Diabetes and Endocrinology, Canberra Health Services, Garran, Canberra, Australia.; School of Medicine and Psychology, Australian National University, Acton, Canberra, Australia., Taylor P; Southern Adelaide Diabetes and Endocrine Services, Oaklands Park, South Australia, Australia., Fenn J; Southern Adelaide Diabetes and Endocrine Services, Oaklands Park, South Australia, Australia., Stranks SN; Southern Adelaide Diabetes and Endocrine Services, Oaklands Park, South Australia, Australia., O'Neal DN; Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia dno@unimelb.edu.au.; Department of Medicine, University of Melbourne, Fitzroy, Victoria, Australia.; Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Victoria, Australia. |
| Source: | BMJ open [BMJ Open] 2025 May 06; Vol. 15 (5), pp. e098457. Date of Electronic Publication: 2025 May 06. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
